*NO COVER LETTER

7802363-3
IPOS COPY
+
IPER + ANNEXES

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 487/04, A61K 31/495 | A1

(11) International Publication Number: WO 97/29109

(43) International Publication Date: 14 August 1997 (14.08.97)

(21) International Application Number: PCT/EP97/00459

(22) International Filing Date: 30 January 1997 (30.01.97)

(30) Priority Data:
60/011,279 7 February 1996 (07.02.96) US
60/027,688 8 October 1996 (08.10.96) US

(71) Applicants *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). NEUROCRINE BIOSCIENCES INC. [US/US]; 3050 Science Park Road, San Diego, CA 92121-1102 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: CHEN, Chen [CN/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US). WEBB, Thomas R. [US/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US). McCARTHY, James R. [US/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US). MORAN, Terence J. [US/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US). WILCOXEN, Keith M. [US/US]; Neurocrine Biosciences Inc., 3050 Science Park Road, San Diego, CA 92121-1102 (US).

(74) Agent: WANTE, Dirk; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).


(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS

(57) Abstract

This invention concerns compounds of formula (I), including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R^1 is NR^4R^5 or OR^5; R^2 is C_{1-6}alkyl, C_{1-6}alkyloxy or C_{1-6}alkylthio; R^3 is hydrogen, C_{1-6}alkyl, C_{1-6}alkylsulfonyl, C_{1-6}alkylsulfoxy or C_{1-6}alkylthio; R^4 is hydrogen, C_{1-6}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, C_{3-6}cycloalkyl, C_{3-6}alkenyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl; R^5 is C_{1-8}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, Ar^1CH_2, C_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{3-6}alkenyl, thienylmethyl, furanylmethyl, C_{1-6}alkylthioC_{1-6}alkyl, morpholinyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)amino, C_{1-6}alkylcarbonylC_{1-6}alkyl, C_{1-6}alkyl substituted with imidazolyl; or a radical of the formula -Alk-O-CO-Ar^1; or R^4 and R^5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).



(I)